We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-4.07%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$8.61B
AUM Growth
-$1.09B
Cap. Flow
-$352M
Cap. Flow %
-4.08%
Top 10 Hldgs %
30.78%
Holding
207
New
16
Increased
51
Reduced
80
Closed
30

Top Buys

Rank Stock Value
1
OM icon
Outset Medical
OM
+$58.4M
2
BSX icon
Boston Scientific
BSX
+$41.2M
3
PACB icon
Pacific Biosciences
PACB
+$38.3M
4
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$37.2M
5
CDNA icon
CareDx
CDNA
+$32.9M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$109M
2
VCRA
VOCERA COMMUNICATIONS, INC.
VCRA
+$75.3M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$73.9M
4
DHR icon
Danaher
DHR
+$66.3M
5
HUM icon
Humana
HUM
+$65.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.39%
2 Industrials 0.69%
3 Energy 0.03%
4 Technology 0.01%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KRYS icon
151
Krystal Biotech
KRYS
$9.88B
$918K 0.01%
13,800
-200
-1% -$12.5K
SLN
152
Silence Therapeutics
SLN
$521M
$887K 0.01%
46,666
– –
NVCR icon
153
NovoCure
NVCR
$2.04B
$704K 0.01%
+8,500
New +$626K
MCK icon
154
McKesson
MCK
$98.5B
$696K 0.01%
2,274
-85
-4% -$23.1K
IDYA icon
155
IDEAYA Biosciences
IDYA
$3.41B
$517K 0.01%
46,200
-800
-2% -$11.8K
GDX icon
156
VanEck Gold Miners ETF
GDX
$23B
$514K 0.01%
+13,400
New +$455K
RDY icon
157
Dr. Reddy's Laboratories
RDY
$9.82B
$474K 0.01%
42,500
– –
RLMD icon
158
Relmada Therapeutics
RLMD
$544M
$432K 0.01%
+16,000
New +$331K
GOOG icon
159
Alphabet (Google) Class C
GOOG
$3.9T
$377K ﹤0.01%
+2,700
New +$367K
EL icon
160
Estee Lauder
EL
$29B
$367K ﹤0.01%
1,348
– –
OPT
161
DELISTED
Opthea Limited American Depositary Shares
OPT
$313K ﹤0.01%
48,000
-1,000
-2% -$6.38K
SWKS icon
162
Skyworks Solutions
SWKS
$9.06B
$280K ﹤0.01%
2,100
– –
MKTX icon
163
MarketAxess Holdings
MKTX
$4.15B
$225K ﹤0.01%
662
– –
MELI icon
164
Mercado Libre
MELI
$91.3B
$202K ﹤0.01%
170
– –
JMIA
165
Jumia Technologies
JMIA
$726M
$172K ﹤0.01%
18,000
– –
AVLR
166
DELISTED
Avalara, Inc.
AVLR
$129K ﹤0.01%
1,300
– –
DLB icon
167
Dolby
DLB
$4.72B
$125K ﹤0.01%
1,600
-2,000
-56% -$161K
IPGP icon
168
IPG Photonics
IPGP
$3.89B
$115K ﹤0.01%
1,050
– –
TSM icon
169
TSMC
TSM
$2.09T
$65K ﹤0.01%
619
+273
+79% +$31.9K
ASR icon
170
Grupo Aeroportuario del Sureste
ASR
$8.03B
$30K ﹤0.01%
135
– –
EQIX icon
171
Equinix
EQIX
$107B
$30K ﹤0.01%
40
– –
EVTC icon
172
Evertec
EVTC
$1.83B
$30K ﹤0.01%
739
– –
INFY icon
173
Infosys
INFY
$45B
$28K ﹤0.01%
1,130
– –
UMC icon
174
United Microelectronic
UMC
$48.9B
$25K ﹤0.01%
2,698
– –
NIO icon
175
NIO
NIO
$11.3B
$23K ﹤0.01%
1,093
+313
+40% +$7.37K
5 6
7
8 9

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q1 2022 Portfolio in Review

As of Q1 2022, Bellevue Group held 207 positions worth $8.61B, down 11% from $9.7B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Bellevue Group withdrew a net $352M in Q1 2022, closing 30 positions and reducing 80 holdings. Its most notable exit was VOCERA COMMUNICATIONS, INC., an estimated $75.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Aurinia Pharmaceuticals worth $29.8M.

  • Bellevue Group's largest Q1 2022 buy was Aurinia Pharmaceuticals: 2,405,825 shares worth $29.8M.
  • Bellevue Group added most to Outset Medical in Q1 2022, an estimated $58.4M increase.
  • Bellevue Group's biggest Q1 2022 reduction was Biogen, cutting an estimated $109M.
  • Bellevue Group fully exited VOCERA COMMUNICATIONS, INC. in Q1 2022, selling an estimated $75.3M.
  • Bellevue Group's ten largest holdings make up 31% of its $8.61B portfolio in Q1 2022.
  • Bellevue Group opened 16 new positions and closed 30 in Q1 2022.
  • Bellevue Group's portfolio value fell 11% quarter-over-quarter to $8.61B.

Based on Bellevue Group's 13F filing for Q1 2022, filed 13 May 2022.